InspireMD (NSPR) Stock Analysis & Winston Score

InspireMD is a medical device company that makes a special type of stent used to open blocked arteries in the neck. Its main product is called the CGuard Embolic Prevention System, which is designed to treat carotid artery disease — a condition where plaque buildup in the neck arteries can cause strokes. The company sells its devices to hospitals and vascular surgeons, primarily in Europe and the United States. InspireMD earns revenue by selling its stents directly to hospitals and through distribution partners. The company is small, with a market cap near zero, and it is not yet profitable — its operating losses are very large relative to its sales. The key growth driver is winning broader adoption in the U.S. market, where the CGuard system received FDA approval in 2023, but the main risk is that the company burns through cash quickly and may need to raise more money to fund ongoing operations and commercialization efforts.